# SAMP review, batch s53 (Toxicology), Lens A second pass (clinical truth)

Lens: A, clinical truth. Scope: the four SAMPs rebuilt in the rework (tox-16, tox-21, tox-28, tox-39 in src/samps/s53/tox.ts) and every SAMP in src/samps/s53/review-extra.ts (tox-48, tox-49). Every SAMP stays reviewed: false. Edits were made only in src/samps/s53/. Gates after the edits: `npx tsc --noEmit -p . 2>&1 | grep samps/s53` prints nothing, and `SAMP_BATCH=s53 npx vitest run tests/samps.test.ts tests/samp-quality.test.ts` gives 743 passed.

## Fix table

| SAMP | Question | Field | Flaw | Confidence |
| --- | --- | --- | --- | --- |
| tox-16 | sources | url | The Marquardt citation pointed to PMID 11553945, which is an intracoronary adenosine paper. The correct PMID is 11555803. | high |
| tox-16 | q3 | prompt, options, key, explanation, source | Keyed bicarbonate for a wide QRS, which repeats the sodium channel blocker teaching in seizures-s49 (bupropion and tricyclic), s03 arrhythmia and s50 shock. Rebuilt around the hydroxychloroquine specific point: epinephrine for hypotension from vasodilation plus myocardial depression (Riou regimen, Marquardt recommendations). Bicarbonate is kept in the explanation with its effect on potassium. | high |
| tox-16 | q4 | explanation | Said the potassium "rebounds ... as bicarbonate is given". Bicarbonate drives potassium further into cells and lowers it, which matters with a QTc of 520 ms. Corrected. This was the writer's point 4. | high |
| tox-16 | q1 | explanation | Named "bicarbonate, potassium and high dose sedation" as the therapy. Replaced with epinephrine, high dose diazepam and close potassium monitoring, which is what the cited source recommends. | medium |
| tox-16 | q2 | explanation | Said pulmonary edema is "not a feature" of this poisoning. It is reported after chloroquine drugs, mostly after large fluid and vasopressor loads. Softened to a later problem rather than the event of the next hour. | low |
| tox-21 | q2 | prompt, options, key, explanation, key feature | Keyed calcium gluconate 3 g first for hyperkalemic ECG changes, the same teaching point (and dose) as s42 ischemic heart disease, s15 pulmonary edema and s03 arrhythmia. Rebuilt as a key feature 5 question on the expected course: the potassium keeps rising because the sustained release tablets keep releasing. | high |
| tox-21 | q4 | explanation | The update says the ECG is unchanged after calcium, yet the explanation never said calcium is repeated. Added. | medium |
| tox-28 | q1 | explanation | Gave enterohepatic recirculation as the reason for multiple dose charcoal. Theophylline is removed mainly by diffusion from the blood back into the gut lumen (gut dialysis). Corrected. | medium |
| tox-28 | q2 | explanation | "Theophylline stimulates beta 2 receptors" is imprecise. It raises catecholamines that stimulate them. Corrected. | low |
| tox-28 | q2 | options, explanation | The propranolol distractor was rejected as "not treatment of the potassium", but nonselective beta blockade does reverse theophylline hypokalemia, and her BP of 104/48 mmHg with a pulse of 136/minute made it partly defensible. Replaced with sodium bicarbonate 50 mmol IV, which would lower potassium further in a patient with pH 7.46. | medium |
| tox-28 | q3 | select, key, explanation | Rejected an acetaminophen level for a deliberate ingestion of 40 tablets, while tox-16 q4 keys it with the correct reason. Added it to the key (select 3 to 4). The earlier Lens A fix to this question was for the old organophosphate case and no longer applies. | high |
| tox-39 | q4 | option, key, explanation | Keyed hydroxocobalamin 1 mg IM. Hydroxocobalamin 1000 mcg/mL injection is cancelled or dormant in the Health Canada Drug Product Database, and cyanocobalamin 1000 mcg IM is the Canadian product. Option changed, key moves from index 1 to index 0. | medium |
| tox-39 | q4 | source | Cited Goldfrank for the treatment, as the writer flagged (point 3). Replaced with Paris et al, Pract Neurol 2023, the neurology practice guide that recommends parenteral B12 and stopping nitrous oxide. | medium |
| tox-39 | q2 | explanation, source | Mechanism sentence implied methylmalonic acid is the substrate of the enzyme nitrous oxide blocks. Reworded to the substrates of the cobalamin dependent enzymes. Source changed to Paris 2023, which supports methylmalonic acid or homocysteine as the functional test. | low |
| tox-39 | q1 | key feature | Tagged key feature 1 (collateral), but the history comes from the patient himself. Not changed. Lens B item for the physician or writer. | low |
| tox-48 (extra) | q1 | correct | Keyed index 0 (magnesium sulfate soaks) while the explanation keys topical calcium gluconate gel. Key set to 3. The first Lens A review recorded this fix, but the file carried the defect again. | high |
| tox-48 (extra) | whole SAMP | overlap | Verbatim copy of tox-26 (same title, stem, vitals and questions), which itself overlaps the hydrofluoric acid cases in s26 burns and s04 burns. Should not be added. | high |
| tox-49 (extra) | q2 | explanation | Invented a serum lactate of 7.8 mmol/L that is not in the stem, and a lactate does not confirm antimuscarinic toxicity. Sentence removed. Also a reappearance of a defect the first Lens A review recorded as fixed. | high |
| tox-49 (extra) | whole SAMP | overlap | Verbatim copy of tox-37 (quetiapine). Should not be added. | high |

## Writer's four points

1. tox-21 calcium gluconate 3 g. Canadian practice gives 1 g to 3 g (10 to 30 mL of 10%) with ECG changes, and Long 2018 recommends 10 mL. The dose was defensible, but the question repeated a bank teaching point and was rebuilt, so no calcium dose is keyed now.
2. tox-28 theophylline thresholds. 210 umol/L is about 38 mg/L. EXTRIP recommends extracorporeal treatment above 100 mg/L (555 umol/L) in acute exposure, or for seizures, life threatening dysrhythmia, shock, a rising level despite optimal therapy or deterioration. The stem sits below all of these and no question keys dialysis, so the omission is sound.
3. tox-39 Goldfrank citation. Replaced by Paris 2023 (above).
4. tox-16 hypokalemia reasoning. The intracellular shift is correct, but the claim that bicarbonate makes it rebound was wrong. Fixed.

## Antidotes and doses checked

- tox-16: epinephrine for hydroxychloroquine hypotension (Marquardt 2001, Riou 1988). No dose keyed.
- tox-21: 60 tablets of 20 mmol is 1200 mmol. Potassium chloride 20 mmol extended release tablets are sold in Canada. Salbutamol 20 mg nebulized and insulin 10 units with dextrose are standard doses. Whole bowel irrigation is named for potassium in the 2015 position paper.
- tox-28: 40 tablets of 300 mg in 58 kg is about 207 mg/kg. 210 umol/L converts to 37.8 mg/L (molar mass 180.16). Magnesium 2 g IV is a standard dose.
- tox-39: cyanocobalamin 1000 mcg IM (Health Canada product monographs). Folic acid, methylprednisolone and pyridoxine distractor doses are plausible.

## Overlap search

Searched src/samps/ for hydroxychloroquine, chloroquine, potassium chloride, theophylline, nitrous oxide, methylmalonic, homocysteine, cobalamin, whole bowel, hydrofluoric, quetiapine, hyperkalemia with calcium, and bicarbonate with QRS.

- Hydroxychloroquine, sustained release potassium chloride, theophylline toxicity and nitrous oxide myeloneuropathy appear as scenarios only in s53. Elsewhere they are write-in list items or procedural sedation uses.
- Teaching point repeats found and rebuilt: tox-16 q3 and tox-21 q2 (above).
- Residual partial overlap, flagged not changed: tox-21 q3 keys whole bowel irrigation for tablets that charcoal does not bind, a principle also keyed for iron in s50 shock and s18 tox. The potassium case is a distinct agent named separately in the position paper, so it was kept. Low confidence.
- Outside my four SAMPs: tox-26 (hydrofluoric acid hands) overlaps s26 burns (calcium gluconate gel after irrigation, systemic fluoride risk). Noted for the coordinator, not edited.

## Key changes

- tox-16 q3: key changed from "sodium bicarbonate 100 mmol IV" (index 4) to "epinephrine infusion IV" (index 1) in a rebuilt question on her hypotension. Reason: teaching point overlap, rebuilt whole.
- tox-21 q2: key changed from "calcium gluconate 3 g IV" (index 0) to "Rise as the tablets keep releasing" (index 2) in a rebuilt key feature 5 question. Reason: teaching point overlap, rebuilt whole.
- tox-28 q3: select 3 to 4, key [2, 4, 5] to [2, 3, 4, 5], adding the acetaminophen level. Reason: deliberate overdose.
- tox-39 q4: option hydroxocobalamin 1 mg IM replaced by cyanocobalamin 1000 mcg IM, key index 1 to 0. Same clinical answer, Canadian product.
- tox-48 q1 (extra): key index 0 to 3. Reason: key contradicted its explanation.

## Sources verified

- Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med. 2001. https://pubmed.ncbi.nlm.nih.gov/11555803/ (URL corrected. Recommends diazepam, early intubation, epinephrine, potassium replacement with close monitoring.)
- Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988. https://pubmed.ncbi.nlm.nih.gov/3336379/ (added)
- Long B, Warix JR, Koyfman A. Controversies in management of hyperkalemia. J Emerg Med. 2018. https://pubmed.ncbi.nlm.nih.gov/29731287/
- Thanacoody R and colleagues. Whole bowel irrigation position paper update. Clin Toxicol. 2015. https://pubmed.ncbi.nlm.nih.gov/25511637/ (names potassium explicitly)
- Ghannoum M and colleagues. EXTRIP theophylline. Clin Toxicol. 2015. https://pubmed.ncbi.nlm.nih.gov/25715736/ (thresholds above)
- Garakani A and colleagues. Nitrous oxide abuse systematic review. Am J Addict. 2016. https://onlinelibrary.wiley.com/doi/10.1111/ajad.12372 (PMID 27037733)
- Paris A, Lake L, Joseph A, et al. Nitrous oxide-induced subacute combined degeneration of the cord: diagnosis and treatment. Pract Neurol. 2023. https://pubmed.ncbi.nlm.nih.gov/36813556/ (added). The companion Association of British Neurologists guide (2023) gives methylmalonic acid or homocysteine by local preference and hydroxocobalamin 1 mg IM.
- Health Canada Drug Product Database: hydroxocobalamin 1000 mcg/mL products cancelled or dormant. https://dhpp.hpfb-dgpsa.ca/dhpp/resource/1259 . Cyanocobalamin 1000 mcg/mL monograph https://pdf.hres.ca/dpd_pm/00070787.PDF

## Needs physician decision

- tox-39 q1 is tagged key feature 1 (collateral) but uses the patient's own history. A physician or writer may add a companion as the informant or retag the question.
- tox-48 and tox-49 duplicate tox-26 and tox-37 and should be rejected rather than added.
- tox-26 overlaps the s26 burns hydrofluoric acid case. Outside this review's scope.

## Summary

Six SAMPs reviewed, all six with defects. 19 table entries: 2 wrong keys or rejected correct answers (tox-28 q3, tox-48 q1), 2 whole questions rebuilt for teaching point overlap (tox-16 q3, tox-21 q2), 1 Canadian product change (tox-39 q4), 2 citation fixes (tox-16 URL, tox-39 source), 2 whole SAMP duplicates (tox-48, tox-49), 1 invented lab value (tox-49), and the rest explanation or mechanism corrections. Most serious: the tox-48 key contradicting its explanation, tox-28 rejecting an acetaminophen level in a deliberate overdose, the tox-16 claim that bicarbonate raises potassium, and the duplicated teaching points in tox-16 and tox-21. Defects found in tox-16, tox-21, tox-28, tox-39, tox-48 and tox-49.
